Zenotech Laboratories narrows Q1FY26 loss as revenue rises 11%
Zenotech Laboratories narrowed its Q1FY26 net loss to ₹45.55 lakh from ₹98.96 lakh in the previous year, while revenue grew 11% to ₹959.64 lakh. The improvement was driven by stable rental income, although total expenses increased by 30%, impacting margins.
*this image is generated using AI for illustrative purposes only.
Zenotech Laboratories Limited reported a narrowed standalone net loss of ₹45.55 lakh for the quarter ended June 30, 2026 (Q1FY26), compared to a loss of ₹98.96 lakh in the corresponding period of FY25. The Hyderabad-based pharmaceutical company posted revenue from operations of ₹959.64 lakh, an 11% increase year-on-year, driven by consistent other operating income primarily derived from rentals for its Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited. This improvement signals early signs of stabilization in cash flows, although operational pressures remain evident in the expense structure.
The Board of Directors approved the unaudited standalone financial results on July 28, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors G S K A & Co., who issued an unmodified review conclusion under Standard on Review Engagements (SRE) 2410. The company also announced that its 37th Annual General Meeting will be held on September 25, 2026, via videoconferencing.
Financial Performance Highlights
Total income for the quarter stood at ₹1,104.79 lakh, up from ₹1,023.16 lakh in Q1FY25. While revenue from operations grew to ₹959.64 lakh from ₹863.91 lakh, other operating income remained stable at ₹101.58 lakh against ₹100.41 lakh previously. Other income declined to ₹43.57 lakh from ₹58.84 lakh.
| Particulars | Q1FY26 (₹ lakh) | Q1FY25 (₹ lakh) | Change |
|---|---|---|---|
| Revenue from operations | 959.64 | 863.91 | +11.1% |
| Other operating income | 101.58 | 100.41 | +1.2% |
| Total Income | 1,104.79 | 1,023.16 | +8.0% |
| Total Expenses | 1,164.86 | 895.48 | +30.1% |
| Profit/(Loss) before tax | (60.07) | 127.68 | Turnaround |
| Net Profit/(Loss) | (45.55) | 98.96 | Loss Narrows |
Expenses rose 30% year-on-year to ₹1,164.86 lakh, largely due to increased employee benefit expenses (₹491.63 lakh vs ₹353.56 lakh) and other expenses (₹483.00 lakh vs ₹364.55 lakh). Depreciation and amortization also increased to ₹190.23 lakh from ₹177.37 lakh. Despite the rise in expenses, the pre-tax position improved significantly from a profit of ₹127.68 lakh in Q1FY25 to a loss of ₹60.07 lakh in Q1FY26, aided by a lower tax expense of ₹(14.52) lakh compared to ₹28.72 lakh in the prior year.
What the Numbers Show
The narrowing of the net loss despite a 30% surge in total expenses highlights the resilience of Zenotech’s core revenue streams. The stability in other operating income, which constitutes roughly 10% of total income, underscores the importance of its asset-leasing strategy to Sun Pharmaceutical Industries Limited. However, the widening gap between total income growth (8%) and expense growth (30%) indicates pressure on operational margins, with employee costs being the primary driver of this divergence. The company’s ability to manage these rising operational costs will be critical for returning to profitability in subsequent quarters.
The company noted that it has no subsidiaries, joint ventures, or associates within the definition of Ind AS 110, as overseas entities in Brazil and the USA were cancelled or revoked, and filings for Nigeria are pending. Consequently, consolidated financial statements are not applicable. Shareholders are advised to update their information with depositories or the RTA to receive the AGM notice.
Historical Stock Returns for Zenotech Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.96% | +5.04% | -3.06% | -0.24% | -17.41% | -11.23% |
What specific cost-control measures is Zenotech implementing to address the 30% surge in employee benefit and other operational expenses?
How might the pending regulatory filings for the Nigerian entity impact Zenotech's future international expansion strategy or consolidated reporting requirements?
Is there a risk of renegotiation or expiration of the lease agreement with Sun Pharmaceutical Industries, which currently provides critical stability to other operating income?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
